Allphase Pharma Consulting, LLC
A Professional Service Provider for the Pharma Industry
Looking at all antibiotics in the pipeline, I can’t help but think that – by 2018 – there will be some blockbuster anti-infectives coming to the market. Why do I say this? What is going to generate this revenue stream for companies when the new crop of drugs will be restricted by Continue reading Why The Next Novel Antibiotic Will Be A Blockbuster And Cost $40k
After a single high dose of (8 or 10 mg/kg BW) of daptomycin IV, bone levels were measured in plasma and trabecular bone obtained during hip or knee surgery of 16 patients.[1] At the time of surgery, mean concentrations in plasma and synovial fluid were 39 and 22 µg/mL, respectively. Continue reading Adequate Penetration of Daptomycin Into Bone Tissue
Several antibiotic classes are associated with QTc prolongation: macrolides, quinolones, the antimalarials that share the quinine structure, and many azole antifungals. FDA warned about the proarrhythmic effects of azithromycin in 2013 [i] but it is a recent publication by Rao which brings the message home again with some very disquieting Continue reading QT Prolongation with Azithromycin and Levofloxacin